Free Trial
→ Everyone’s watching Nvidia right now. Here’s why I’m excited. (From Timothy Sykes) (Ad)
TSE:BCT

BriaCell Therapeutics 6/14/2023 Earnings Report

C$4.22 -0.65 (-13.35%)
As of 06/13/2025 04:00 PM Eastern
ProfileEarnings History

BriaCell Therapeutics EPS Results

Actual EPS
-C$0.43
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

BriaCell Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BriaCell Therapeutics Announcement Details

Quarter
Date
6/14/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

BriaCell Therapeutics Earnings Headlines

BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+(TM) Development
April 30, 2025 | stockhouse.com
BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC) - Morningstar
April 23, 2025 | morningstar.com
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
June 15, 2025 | Brownstone Research (Ad)
BriaCell Therapeutics Corp.: BriaCell Announces Completion of 15:1 Share Consolidation
January 28, 2025 | finanznachrichten.de
See More BriaCell Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BriaCell Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BriaCell Therapeutics and other key companies, straight to your email.

About BriaCell Therapeutics

BriaCell Therapeutics (TSE:BCT) operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

View BriaCell Therapeutics Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles